Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zepatier to Prevent HCV Transmission in Kidney Transplant Recipients
NCT03093740Phase 4Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- Oct 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of grazoprevir in hepatitis C (HCV), sponsored by Massachusetts General Hospital. Planned start Oct 2018; status: withdrawn.
02
Drugs
grazoprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03093740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03093740.